Introduction
Osteosarcoma (OS) is the most common primary malignant bone tumor in children, adolescents, and young adults. 1 Despite recent advances in the diagnosis and management of OS, such as surgery and multi-agent chemotherapy, the clinical outcomes and prognosis of OS patients remains poor over the past few decades mainly due to tumor recurrence, metastasis, and poor response to chemotherapy and radiotherapy. 2 Thus, there is a critical need to elucidate the potential mechanism that mediates the initiation and progression of OS for improving its treatment strategies.
MicroRNAs (miRNAs) are small (18-25 nucleotides in length), endogenous noncoding RNAs that negatively regulate the expression of target genes by binding to the 3'-untranslated region (3'-UTR) of their target messenger differentiation. 4, 5 MiRNAs have been implicated in human carcinogenesis as oncogenes or tumor suppressors. 6, 7 Indeed, some miRNAs have been showed to play crucial roles in development and progression of OS and can serve as diagnostic markers and therapeutic targets. 8, 9 MiR-25, a member of the miR-106b-25 cluster which consists of miR-106b, miR-25, miR-93, miR-363-3p, and miR-367, has been reported to be involved in progression and development of many types of cancers. 10 Although a study showed that miR-25 was downregulated in OS tissues, 11 the precise roles of miR-25 in OS remains unclear. In this study, we found that miR-25 expression was downregulated in OS tissues and cell lines. Further functional investigation demonstrated that miR-25 repressed tumor growth in vitro and in vivo. Importantly, we identified SOX4 as the direct target of miR-25 in OS. These findings provide significant clues regarding the role of miR-25 as a tumor suppressor in OS by repressing SOX4.
Materials and methods

Tissue specimens, cell lines, and cell transfection
A total of 36 pairs of OS and adjacent normal tissues (located >3 cm from the tumor) were harvested from OS patients who underwent surgery at Department of Orthopedics, the Second Hospital of Jilin University (Changchun, China) between July 2015 and July 2016. All samples were immediately placed in liquid nitrogen until RNA extraction. Demographic and clinicopathological information of OS patients were harvested and listed in Table 1 . All patients had provided consents and this study was approved by the Ethics Committee of Jilin University (Changchun, China) and complied with the Declaration of Helsinki.
Four human OS cell lines (Saos-2, HOS, U2OS, and MG63) and normal human osteoblasts, hFOB 1.19, were brought from Shanghai Institute for Biological Sciences (Shanghai, China). All cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) and supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA), 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C in 5% CO 2 .
MiR-25 mimic and corresponding scramble control (miR-Ctrl) were brought from RiboBio (Guangzhou, China). The overexpressing SOX4 plasmid (pCDNA3.1-SOX4) was granted by Dr Ying Jin (Jilin University). The mimic or plasmid was transfected into cells at 50%-70% confluence using Lipofectamine 2000 (Invitrogen) according to the manufacturer's recommendations.
Real-time quantitative polymerase chain reaction
The expression of miR-25 or SOX4 mRNA in tissues or cells was detected using real-time polymerase chain reaction (PCR). Total RNA extraction from tissues or cells was performed using TRIzol reagent (Invitrogen). RNA quantity and integrity were determined using Thermo NanoDrop 2000 (Thermo Fisher Scientific, Cleveland, OH, USA). Reverse transcription assay and real-time PCR assay were performed using PrimeScript RT reagent Kit (TaKaRa, Dalian, China) and SYBR Premix Ex Taq II (Tli RNaseH Plus) kit (TaKaRa), respectively, under ABI 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The primes of miR-25 and U6 were brought from Applied Biosystems. The primes of SOX4 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used in this study as described previously. 12 U6 and GAPDH were used for miRNA and mRNA normalization, respectively. The relative expression of SOX4 mRNA or miR-25 was quantified using the 2 -∆∆Ct method.
Cell proliferation and colony formation assays
Cell proliferation was determined using Cell Counting Kit-8 (CCK-8) assay (Dojindo, Kumamoto, Japan) according to the manufacturer's instruction. The absorbance at 450 nm was detected in a microtiter plate reader (Molecular Devices, Menlo Park, CA, USA) at 24, 48, and 72 h post-transfection. For colony formation assay, 1000 transfected cells were seeded into six-well plates and cultured for 10 days. The medium was replaced every 3 days. The colonies were photographed and counted using a phase-contrast microscope (Olympus, Tokyo, Japan) after staining with 0.5% crystal violet solution (Sigma Aldrich, St. Louis, MO, USA).
Cell migration and invasion assays
Briefly, the transfected cells were seeded in six-well plates and allowed to reach to 100% confluence. Wounds were then scratched on the monolayer of cells using a sterile plastic micropipette tip. Cells were rinsed with phosphatebuffered saline (PBS) and cultured in serum-free medium for 24 h. Wound closure was observed at 0 and 24 h and photographed under a microscope (Olympus).
Cell invasion ability was analyzed using Transwell chambers (8 mm pore size; Corning Inc., Corning, NY, USA) pretreated with Matrigel (Millipore, Billerica, MA, USA). Briefly, 2 × 10 4 transfected cells suspended in serum-free medium were added to the upper chamber, and DMEM supplemented with 10% FBS was added to the lower chamber. After 48 h cultivation, cells still in the upper chambers were removed with cotton swab carefully, whereas the cells that invaded the lower chamber were fixed in with 4% formaldehyde and subsequently were stained with 0.1% crystal violet. Invasive cells were observed under an inverted microscope (Olympus) and counted in five randomly selected fields.
Dual-luciferase assay
Wild-type SOX4-3'-UTR (WT-SOX4) containing the putative miR-25 binding site and corresponding mutant SOX4-3'-UTR (MUT-3'-UTR) were cloned into pGL3 luciferase promoter vector (Promega, Madison, WI, USA). Cells were seeded in a 96-well plate for 24 h. Then, cells were cotransfected with WT-SOX4 or MUT-SOX4 reporter plasmid and miR-25 mimic or miR-Ctrl using Lipofectamine 2000. Relative luciferase activity was detected using Dual-Luciferase Reporter Assay System (Promega) 48 h after transfection.
Western blotting
The protein was extracted by lysing cells in radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase inhibitors (Beyotime, Jiangsu, China). The protein concentration was quantified with the bicinchoninic acid (BCA) kit (Pierce, Rockford, IL, USA). Aliquots of protein lysates were separated by 8%-10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membranes (Merck, Millipore, Germany). The membranes were blocked in 5% (w/v) nonfatty milk powder in Tris-buffered saline (TBS; 20 mM Tris-HCl, pH 7.5, 150 mM NaCl) at room temperature for 1 h and then were probed with antibodies against SOX4 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), E-cadherin (1:1000; Santa Cruz Biotechnology), N-cadherin(1:1500; Santa Cruz Biotechnology), and vimentin (Cell Signaling Technology, Danvers, MA, USA) or GAPDH (1:3000; Santa Cruz Biotechnology) in TBS overnight at 4°C. After washed three times with TBS containing 0.1% Tween-20 (TBST), the membranes were incubated with the corresponding secondary antibodies (Santa Cruz Biotechnology) for 1 h at room temperature. The protein bands were observed with enhanced chemiluminescence detection system (ECL; Thermo Fisher Scientific). GAPDH was used as a control.
In vivo tumourigenesis assay
U2OS cells (2 × 10 6 cells per mouse) were inoculated subcutaneously into the dorsal flanks of 6-week-old male nude mice (Laboratory Animal Research Center of Jilin University). On day 14, when tumors reached ~100 mm 3 , miR-25 mimic or miR-Ctrl (100 nM per mouse in 100 μL total volume containing 90 μL PBS and 10 μL Lipofectamine 2000; five mice per group) was injected directly into the tumors with 26-gauge needles every 7 days for 28 days. The tumor width and length were measured every 7 days using a caliper. Tumor volume was calculated by the formula: V (volume) = 1/2 × length × width 2 . Mice were killed by cervical dislocation on the 28th day after injection, and tumor tissues were stripped and weighted. Tumor tissues were snap-frozen and stored in liquid nitrogen until use. All experimental procedures were approved by the Institutional Animal Ethics Committee of Jilin University.
Statistical analysis
All data were analyzed using SPSS version 19.0 (IBM, Armonk, New York, USA) and expressed as the mean ± standard deviation (SD) at least three times by independent experiments. Differences between two groups and among three or more groups were measured by Student's t-test and oneway analysis of variance (ANOVA), respectively. The relationship between SOX4 and miR-25 expression was tested with two-tailed Pearson's correlation analysis. In all cases, a p < 0.05 was considered statistically significant.
Results
MiR-25 is downregulated in OS tissues and cell lines
To detect miR-25 status in OS, the expression level of miR-25 in 36 OS specimens and adjacent normal tissues was detected. The results of qPCR showed that the expression of miR-25 was downregulated in OS tissues compared with their adjacent normal tissues (Figure 1(a) ). To determine the correlation between miR-25 expression and clinicopathological characteristics of OS, we divided the OS patient into two groups according to mean value of miR-25 in all patients: high expression groups (n = 16) and low expression group (n = 20). As shown in Table 1 , no statistical difference was demonstrated in the correlation between miR-25 expression and age, sex, and tumor size, whereas reduced miR-25 might be associated with tumornode-metastasis (TNM) stage and lymph node metastases (p < 0.05; Table 1 ). Moreover, miR-25 expression in four OS cell lines (Saos-2, HOS, U2OS, and MG63) was lower than the normal human osteoblastic cell line, hFOB 1.19 (all p < 0.05; Figure 1(b) ).
miR-25 suppresses the OS cells' proliferation and colony formation
To explore the potential role of miR-25 in OS cell proliferation, miR-25 mimic or miR-Ctrl was transfected into U2OS cells which has lowest expression of miR-25 in four OS cell lines (Figure 1(b) ), and then, cell proliferation and colony formation were determined. The efficiency of miR-25 transfection was confirmed by qPCR (Figure 2(a) ). CCK-8 assay showed that restored expression of miR-25 inhibited U2OS cell proliferation (Figure 2(b) ). Consistent with these results, restored expression of miR-25 also significantly inhibited colony formation in U2OS cells (Figure 2(c) ).
MiR-25 suppresses the OS cells' migration and invasion
To understand the effect of miR-25 on migration and invasion ability of OS cells, wound-healing and Transwell invasion assays were performed. The data demonstrated that the migratory and invasive ability of U2OS cells was significantly suppressed in miR-25 mimic group compared with miR-Ctrl group (Figure 3 
SOX4 is a direct target of miR-25 in OS
Using TargetScan, we identified SOX4 as the tentative target of miR-25 (Figure 4(a) ). To confirm this possibility, luciferase reporter assay was performed. The result showed that U2OS cells transfected with miR-25 mimic significantly inhibited WT-SOX4-3'-UTR reporter activity (p < 0.01; Figure 4(b) ), while they had no inhibitory effect on the MUT-SOX4 3'-UTR reporter activity (Figure 4(b) ). Moreover, restored expression of miR-25 also repressed the mRNA and protein expression of SOX4 in U2OS cells (Figure 4(c) and (d) ). SOX4 has been suggested to act as a regulator of epithelial-mesenchymal transition (EMT). Therefore, we wonder whether miR-25 can regulate EMT by detecting the expression of EMT markers, epithelial marker, E-cadherin and mesenchymal markers, N-cadherin, and vimentin in U2OS cells after transfected with miR-25 mimic or miR-Ctrl. The result of western blot demonstrated that restored expression of miR-25 significantly upregulated E-cadherin expression and decreased N-cadherin and vimentin expression ( Figure 4(d) ). These results suggested that SOX4 was a target of miR-25 in OS. 
SOX4 was upregulated in OS tissues and inversely correlated with miR-25 expression
We next detected the SOX4 mRNA expression in 36 OS tissues and corresponding adjacent normal tissues by qPCR and found that SOX4 mRNA expression was upregulated in OS tissues compared to adjacent normal tissues ( Figure  5(a) ). Through Pearson's correlation analysis, the SOX4 mRNA level was inversely correlated with miR-25 expression in OS tissues (r = −0.617; p < 0.001; Figure 5(b) ). Moreover, SOX4 expression also was upregulated on mRNA level and protein level in four OS cell lines (Saos-2, HOS, U2OS, and MG63) compared to normal human osteoblastic cell line, hFOB 1.19 (Figure 5(c) and (d) ).
Tumor-suppressing function of miR-25 rescued by SOX4
To determine whether miR-25 inhibited the proliferation and invasion of OS cells by repressing SOX4, we transduced SOX4-overexpressing plasmid together with the miR-25 mimic into U2OS cells. The expression of SOX4 was verified by qPCR and western blot analysis. As shown in Figure 6 (a) and (b), cotransfection with SOX4 overexpression plasmid and miR-25 mimic significantly increased SOX4 expression level compared to transfection with miR-25 mimic alone. Moreover, reintroduction of SOX4 partially reversed the inhibitory effects of the miR-205 mimic on cell proliferation, colony formation, migration, and invasion of OS cells (Figure 6(c)-(f) ).
MiR-25 suppressed tumor growth in vivo
To determine the effects of miR-25 on tumorigenicity in vivo, miR-25 mimic or miR-Ctrl was injected directly into the tumors. After 4 weeks, we found that injection with miR-25 mimic increased the intratumoural levels of miR-25 (Figure 7(a) ) and repressed the growth of U2OS xenografts compared with miR-Ctrl-injected tumor (Figure  7(b) ). Consistent with the tumor growth curve, the size and weight of tumor injected with miR-25 were significantly decreased compared to miR-Ctrl-injected tumor (Figure 
7(c) and (d)
). In addition, the expression of SOX4 on mRNA level and protein level was downregulated in miR-25-injected tumors compared to miR-Ctrl-injected tumor (Figure 7 (e) and (f)). These results suggested that miR-25 suppressed tumor growth in vivo by targeting SOX4.
Discussion
In this study, we investigated the expression and function of miR-25 in OS. We found that the miR-25 expression was downregulated in OS tissues and cell lines and that decreased miR-25 was negatively associated with advanced TNM stage and lymph node metastasis. Further investigation demonstrated that miR-25 suppressed cell proliferation, colony formation, migration, and invasion in U2OS cells and retarded tumor growth in vivo. Mechanistically, SOX4 was identified as a direct target of miR-25 in OS, in which SOX4 was upregulated and showed inverse correlation with miR-25 in OS tissues. In addition, we demonstrated that enforced expression of SOX4 reversed the inhibitory effect of miR-25 on cell proliferation, migration, and invasion of OS cells. These data suggest that miR-25 restricted the development of OS by targeting SOX4.
MiR-25, located on chromosome 7 (7q22.1) in the 13th intron of the MCM7 gene, 13 has been reported to be involved in multiple biological procession, including proliferation, invasion, differentiation, apoptosis, and autophagy. 10 MiR-25 expression was upregulated in multiple types of cancers, such as non-small-cell lung cancer, 14 breast cancer, 15 ovarian cancer, 16 gastric cancer, 17 and cervical cancer, 18 functioning as oncogene in these cancers. On the contrary, in glioblastoma multiforme, 19 colon cancer, 20 and tongue squamous cell carcinoma, 21 miR-25 was found to be downregulated and functioned as tumor suppressor. These findings suggested that the functional role of miR-25 in different cancers might be paradoxical. Although a study showed that miR-25 was downregulated in OS tissues, 11 the roles and underlying mechanism of miR-25 in OS remain largely unknown. In this study, we found that miR-25 overexpression inhibited OS cell proliferation, colony formation, migration, and invasion in vitro and suppressed tumor growth in vivo. These results, linking to previous a study, suggested that miR-25 might function as tumor suppressor in OS.
SOX4, a member of the Sex-determining region Y-related high-mobility group box (Sox) transcription factor family, 22 has been reported to be upregulated in multiple human cancers including OS. 23 Growing evidence suggested that overexpression of SOX4 could promote tumor progression and metastasis. 24, 25 In addition, SOX4 was shown to regulate several key signaling pathways in cancer cells such as the Wnt pathway, Notch1 pathway, and P53 pathway. 26, 27 Of note, SOX4 could serve as a master mediator in EMT process by regulating EMT marker, 28, 29 which is a critical step in tumor progression and metastasis. 30 In this study, SOX4 was identified as a direct target of miR-25 by a luciferase reporter assay, quantitative reverse transcription polymerase chain reaction (qRT-PCR), and western blot. MiR-25 overexpression significantly increased E-cadherin expression and decreased N-cadherin and vimentin expression, which contributed to inhibiting EMT procession. SOX4 expression level was upregulated and negatively correlated with miR-25 expression levels in human OS tissues. SOX4 overexpression reversed the inhibition effects on cell proliferation, colony formation, migration, and invasion induced by miR-25 in OS cells. These results suggest that miR-25 functions as a tumor suppressor, at least in part, by repressing SOX4 expression.
In conclusion, this study demonstrated that miR-25 expression was downregulated in OS tissues and cell lines and were closely associated with TNM stage and lymph node metastasis; also, miR-25 overexpression restrained proliferation, colony formation, migration, and invasion of OS cells in vitro as well as suppressed tumor growth in vivo by directly targeting SOX4. Further studies are required to clarify the effect of other miR-25 targets in OS and if any synergic relationship exists. However, taking into consideration the significant effect of miR-25/SOX4 axis, miR-25 itself and its target might be a potential target for treatment of OS in the future.
